Systematic Review of Drug Nanocarriers in Breast Cancer Treatment: Focusing on Liposomes and Polymeric Nanoparticles
نویسندگان
1 International School of Finance and Technology, Tashkent region, Tashkent, Uzbekistan
2 Department of Pharmaceutics, College of Pharmacy, University of Al-Ameed, Karbala, Iraq
3 Department of Pharmacy, Al-Noor University College, Nineveh, Iraq
4 Department of dentistry, Al-Manara College For Medical Sciences, Maysan, Iraq
5 Department of dentistry, Mazaya University College, Iraq
6 Scientific and Practical Medical Center for Dermatovenerology and Cosmetology, Ministry of Health of the Republic of Uzbekistan, Uzbekistan
7 Bukhara regional teacher training institute, Bukhara, Uzbekistan
8 Department of pharmaceutics, Faculty of pharmacy, Al-Turath University, Baghdad, Iraq
9 Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq
10 Department of dentistry, Al-Hadi University College, Baghdad, 10011, Iraq
11 Termez State University, Termez , Uzbekistan
12 Termez State University, Termez , Uzbekistan
13 Polyclinic of the Republican Specialized Primary Practical Medical Center for Mother and Child, Uzbekistan
doi
10.22052/JNS.2023.04.006چکیده
Breast cancer remains one of the most prevalent and challenging cancers to treat, necessitating advancements in therapeutic strategies. This systematic review aims to evaluate the efficacy of drug nanocarriers, with a specific focus on liposomes and polymeric nanoparticles, in the treatment of breast cancer. Utilizing a comprehensive search strategy across multiple databases, we identified and analyzed relevant studies that investigate the use of these nanocarriers in breast cancer therapy. Our findings indicate that both liposomes and polymeric nanoparticles offer significant advantages in targeted drug delivery, enhanced therapeutic efficacy, and reduced systemic toxicity compared to conventional treatment methods. Liposomes, due to their biocompatibility and ability to encapsulate both hydrophilic and hydrophobic drugs, have shown promising results in clinical trials. Polymeric nanoparticles, with their customizable properties and sustained drug release capabilities, also demonstrate substantial potential in breast cancer treatment. However, each type of nanocarrier presents unique challenges in terms of stability, scalability, and regulatory approval. This review highlights the key advancements, comparative efficacy, and future prospects of liposomes and polymeric nanoparticles, underscoring their critical role in advancing breast cancer therapeutics.
